RNAi platform with big pharma validation (J&J, GSK, Takeda partnerships). Plozasiran competes in FCS with IONS's TRYNGOLZA but the broader pipeline (zodasiran, pulmonary, CNS) gives platform optionality. Partner-funded development reduces cash burn.
Conviction●●●○○3 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$11.83BSnapshot value
Plozasiran FCS regulatory decision, plozasiran Ph3 CVOT enrollment progress, zodasiran lipid disorder data, new partnership announcements, existing partner milestone payments
1. Plozasiran rejected or severely label-restricted by FDA. 2. IONS TRYNGOLZA dominates FCS — ARWR locked out. 3. TRiM platform delivery fails in key tissue targets. 4. Partner attrition — J&J/GSK terminate collaborations. 5. Dilutive financing before profitability.
Moderate retail interest driven by RNAi narrative and J&J partnership. High short ratio (7.9) signals skepticism.
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed